SITARI PHARMACEUTICALS
Sitari Pharmaceuticals is a operator of a biotechnology company intended to develop treatments for multiple disease indications with an initial focus in celiac disease.
SITARI PHARMACEUTICALS
Industry:
Biopharma Biotechnology Health Care Intellectual Property Pharmaceutical Robotics
Founded:
2013-01-01
Address:
San Diego, California, United States
Country:
United States
Status:
Active
Total Funding:
10 M USD
Similar Organizations
Actinogen Medical
Actinogen Medical is biotechnology company developing innovative treatments for Alzheimer's disease and the cognitive.
Adamis Pharmaceuticals
Adamis Pharmaceuticals is a biopharmaceutical company developing therapeutics for respiratory diseases and cancer.
AZTherapies
AZTherapies is a clinical stage biotech company developing breakthrough treatments for neuroinflammation-related diseases.
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
ERS Genomics
ERS Genomics is a biotechnology company to provide broad access to the foundational CRISPR-Cas9 intellectual property.
Neurana Pharmaceuticals
Neurana Pharmaceuticals is currently developing a novel treatment for acute muscle spasms.
Reactive Medical Labs
Reactive Medical Labs is a biotechnology company developing regenerative skincare applications.
Somai Pharmaceuticals Ltd
Somai is a European pharmaceutical and biotech company concentrating on cannabinoid-containing pharmaceutical medicines.
Visionary Pharmaceuticals
Visionary Pharmaceuticals is a biotechnology company developing first-in-class drugs for unmet medical needs in cancer and inflammation.
Current Employees Featured
Founder
Investors List
GlaxoSmithKline
GlaxoSmithKline investment in Series A - Sitari Pharmaceuticals
Avalon Ventures
Avalon Ventures investment in Series A - Sitari Pharmaceuticals
More informations about "Sitari Pharmaceuticals"
GSK buys celiac startup Sitari 6 years after founding it with Avalon
Sep 11, 2019 Sitari raised a $10 million series A round in the same year and then worked within Avalon’s COI Pharmaceuticals incubator to develop intellectual property in-licensed from …See details»
Sitari Pharmaceuticals - Crunchbase Company Profile & Funding
Organization. Sitari Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. ... Sitari Pharmaceuticals is a operator of a biotechnology …See details»
GSK drops celiac disease program acquired in Sitari …
GSK bought Sitari in 2019 and took its lead candidate, GSK3915393, into the clinic the following year. GSK completed the study in 2021, but the candidate …See details»
GSK to Acquire Celiac-Focused Sitari Pharmaceuticals
Sep 11, 2019 Building on its unique six-year relationship with Avalon Ventures, GlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and its transglutaminase 2 small …See details»
GSK to buy Sitari Pharmaceuticals from Avalon Ventures
UK-based pharmaceutical company GlaxoSmithKline (GSK) has signed a definitive agreement with Avalon Ventures to acquire Sitari Pharmaceuticals for an undisclosed amount. The deal covers the acquisition of the company, as …See details»
GSK buys Avalon-partnered Sitari and its coeliac drug
Sep 11, 2019 Sitari was the first company created as a result of a 2013 alliance with Avalon that was set up to fund and launch early-stage life science companies at Avalon’s COI Pharma incubator in San ...See details»
GSK takes over full ownership of Sitari Pharmaceuticals
Sep 12, 2019 Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at …See details»
Avalon Ventures and COI Pharmaceuticals Announce Acquisition …
Sep 11, 2019 GSK to acquire Sitari Pharmaceuticals, which has been developing a transglutaminase 2 small molecule program for the treatment of celiac disease. Avalon …See details»
Sitari Pharmaceuticals - BioSpace
Sep 11, 2019 Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK. September 11, 2019 · 3 min read. AWARDS. BioSpace is the digital …See details»
GlaxoSmithKline’s Acquisition Of Sitari …
Sep 13, 2019 Avalon Ventures recently announced that it entered a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari is known for developing a novel treatment for …See details»
GSK acquires Sitari Pharmaceuticals | C&EN Global Enterprise
Sep 16, 2019 GlaxoSmithKline will acquire Sitari Pharmaceuticals for an undisclosed sum. GSK and venture capital firm Avalon Ventures founded Sitari in 2013. GSK and Avalon struck a …See details»
GSK Buys Celiac Startup Sitari 6 Years After Founding It With Avalon
Sep 16, 2019 GlaxoSmithKline has struck a deal to buy Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures. Sitari, a preclinical-stage …See details»
GSK buying Sitari Pharmaceuticals - Chemical & Engineering News
Sep 14, 2019 GSK and venture capital firm Avalon Ventures founded Sitari in 2013. GSK and Avalon struck a deal at the time to fund up to 10 biotech start-ups at Avalon’s incubator, COI …See details»
Sitari Pharmaceuticals - VentureRadar
Sitari Pharmaceuticals is targeting the Transglutaminase 2 (TG2) pathway for the development of treatments for multiple disease indications, with an initial focus in celiac disease. Celiac …See details»
Sitari Pharmaceuticals - Funding, Financials, Valuation & Investors
Sitari Pharmaceuticals is a biotechnology company developing treatments for multiple disease indications. New. Resources. ... Experience the new Crunchbase, powered by AI . Experience …See details»
Sitari Pharmaceuticals - Products, Competitors, Financials, …
Sitari Pharma is developing treatments for celiac disease, an autoimmune digestive disease caused by intolerance to gluten, a protein found in wheat, rye and barley that damages the …See details»
Avalon Ventures and COI Pharmaceuticals Announce Acquisition …
Sep 13, 2019 GSK to obtain transglutaminase 2 small molecule program for celiac disease. SAN DIEGO--(BUSINESS WIRE)--Avalon Ventures today announced that it entered into a definitive …See details»
Avalon Ventures and COI Pharmaceuticals Announce First …
May 20, 2016 Sitari Pharmaceuticals, which is developing novel treatments for celiac disease, and Silarus Therapeutics, which is developing novel treatments for iron overload disorders, …See details»
Progress in celiac disease leads GSK to buy San Diego’s Sitari
Sep 11, 2019 Sitari Pharmaceuticals, the first San Diego life science company founded under a groundbreaking partnership between La Jolla’s Avalon Ventures and GlaxoSmithKline (GSK) …See details»
US tariffs on pharmaceuticals could hit Chinese export firms’ profit ...
12 hours ago Chinese drug makers could face squeezed profit margins, as US President Donald Trump is expected to press ahead with tariffs on pharmaceuticals despite his pledge to slash …See details»